Insufficient scRNA-seq data for expression of MR1 at single-cell level.
Insufficient scRNA-seq data for expression of MR1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 1843.56 | 653 / 653 | 100% | 25.61 | 603 / 605 |
kidney | 100% | 1483.69 | 89 / 89 | 99% | 19.23 | 894 / 901 |
breast | 100% | 1451.02 | 458 / 459 | 99% | 17.84 | 1106 / 1118 |
lung | 100% | 2271.10 | 577 / 578 | 98% | 18.70 | 1130 / 1155 |
esophagus | 100% | 1691.86 | 1445 / 1445 | 96% | 11.72 | 175 / 183 |
bladder | 100% | 2127.33 | 21 / 21 | 95% | 13.57 | 479 / 504 |
uterus | 100% | 1660.25 | 170 / 170 | 95% | 14.90 | 435 / 459 |
skin | 100% | 1925.18 | 1808 / 1809 | 93% | 14.41 | 439 / 472 |
adrenal gland | 100% | 1930.38 | 258 / 258 | 88% | 10.72 | 202 / 230 |
ovary | 100% | 1647.72 | 180 / 180 | 86% | 7.21 | 371 / 430 |
prostate | 100% | 1769.18 | 245 / 245 | 82% | 6.73 | 411 / 502 |
intestine | 100% | 1409.09 | 963 / 966 | 78% | 5.89 | 409 / 527 |
stomach | 93% | 867.65 | 334 / 359 | 83% | 6.73 | 237 / 286 |
pancreas | 75% | 375.41 | 247 / 328 | 97% | 14.22 | 173 / 178 |
liver | 94% | 541.20 | 212 / 226 | 78% | 5.95 | 318 / 406 |
brain | 66% | 371.03 | 1756 / 2642 | 90% | 9.46 | 633 / 705 |
blood vessel | 100% | 2568.62 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 17.09 | 29 / 29 |
spleen | 100% | 2216.61 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.11 | 1 / 1 |
adipose | 100% | 1447.45 | 1203 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 2636.39 | 918 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 15.15 | 44 / 45 |
eye | 0% | 0 | 0 / 0 | 86% | 10.32 | 69 / 80 |
heart | 82% | 637.74 | 706 / 861 | 0% | 0 | 0 / 0 |
muscle | 39% | 169.24 | 316 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0002474 | Biological process | antigen processing and presentation of peptide antigen via MHC class I |
GO_0002854 | Biological process | positive regulation of T cell mediated cytotoxicity directed against tumor cell target |
GO_0045087 | Biological process | innate immune response |
GO_0050829 | Biological process | defense response to Gram-negative bacterium |
GO_0033077 | Biological process | T cell differentiation in thymus |
GO_0006955 | Biological process | immune response |
GO_0050830 | Biological process | defense response to Gram-positive bacterium |
GO_0019884 | Biological process | antigen processing and presentation of exogenous antigen |
GO_0005615 | Cellular component | extracellular space |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0031902 | Cellular component | late endosome membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0031901 | Cellular component | early endosome membrane |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0042612 | Cellular component | MHC class I protein complex |
GO_0042608 | Molecular function | T cell receptor binding |
GO_0032393 | Molecular function | MHC class I receptor activity |
GO_0030881 | Molecular function | beta-2-microglobulin binding |
GO_0005515 | Molecular function | protein binding |
Gene name | MR1 |
Protein name | Major histocompatibility complex class I-related gene protein (MHC class I-related gene protein) (Class I histocompatibility antigen-like protein) Major histocompatibility complex, class I-related Major histocompatibility complex class I-related gene protein |
Synonyms | |
Description | FUNCTION: Antigen-presenting molecule specialized in displaying microbial pyrimidine-based metabolites to alpha-beta T cell receptors (TCR) on innate-type mucosal-associated invariant T (MAIT) cells . In complex with B2M preferentially presents riboflavin-derived metabolites to semi-invariant TRAV1-2 TCRs on MAIT cells, guiding immune surveillance of the microbial metabolome at mucosal epithelial barriers . Signature pyrimidine-based microbial antigens are generated via non-enzymatic condensation of metabolite intermediates of the riboflavin pathway with by-products arising from other metabolic pathways such as glycolysis. Typical potent antigenic metabolites are 5-(2-oxoethylideneamino)-6-D-ribitylaminouracil (5-OE-RU) and 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU), products of condensation of 5-amino-6-D-ribityaminouracil (5-A-RU) with glyoxal or methylglyoxal by-products, respectively . May present microbial antigens to various TRAV1-2-negative MAIT cell subsets, providing for unique recognition of diverse microbes, including pathogens that do not synthesize riboflavin . Upon antigen recognition, elicits rapid innate-type MAIT cell activation to eliminate pathogenic microbes by directly killing infected cells . During T cell development, drives thymic selection and post-thymic terminal differentiation of MAIT cells in a process dependent on commensal microflora (By similarity). Acts as an immune sensor of cancer cell metabolome . May present a tumor-specific or -associated metabolite essential for cancer cell survival to a pan-cancer TCR consisting of TRAV38.2-DV8*TRAJ31 alpha chain paired with a TRBV25.1*TRBJ2.3 beta chain on a non-MAIT CD8-positive T cell clone (MC.7.G5), triggering T cell-mediated killing of a wide range of cancer cell types . . |
Accessions | ENST00000684662.1 Q95460 ENST00000617803.5 ENST00000367580.6 [Q95460-1] A0A8C8PVM5 A0A804HJC9 ENST00000367579.7 [Q95460-2] ENST00000434571.7 [Q95460-5] A0A804HIG0 ENST00000614012.5 [Q95460-1] ENST00000683652.1 ENST00000282990.10 [Q95460-3] |